![](https://static.wixstatic.com/media/cd6738_b1796c7560384018bccfbdf287731bda~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_b1796c7560384018bccfbdf287731bda~mv2.webp)
![NCT05288062: Phase 2: Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) + Dex](https://static.wixstatic.com/media/cd6738_b1796c7560384018bccfbdf287731bda~mv2.jpg/v1/fill/w_269,h_180,fp_0.50_0.50,q_90,enc_auto/cd6738_b1796c7560384018bccfbdf287731bda~mv2.webp)
- Dec 1, 2022
NCT05288062: Phase 2: Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) + Dex
![](https://static.wixstatic.com/media/cd6738_594d850e35ea43d98e532e9746f34c1e~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_594d850e35ea43d98e532e9746f34c1e~mv2.webp)
![NCT04398745: Phase 1: Belantamab Mafodotin With Normal and Varying Degree of Impaired Renal Function](https://static.wixstatic.com/media/cd6738_594d850e35ea43d98e532e9746f34c1e~mv2.jpg/v1/fill/w_269,h_181,fp_0.50_0.50,q_90,enc_auto/cd6738_594d850e35ea43d98e532e9746f34c1e~mv2.webp)
- Dec 23, 2021
NCT04398745: Phase 1: Belantamab Mafodotin With Normal and Varying Degree of Impaired Renal Function
![](https://static.wixstatic.com/media/cd6738_658c597ecc2c4304901bec9241638708~mv2.jpeg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_658c597ecc2c4304901bec9241638708~mv2.webp)
![NCT05024045: Phase 1 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers](https://static.wixstatic.com/media/cd6738_658c597ecc2c4304901bec9241638708~mv2.jpeg/v1/fill/w_269,h_182,fp_0.50_0.50,q_90,enc_auto/cd6738_658c597ecc2c4304901bec9241638708~mv2.webp)
- Dec 12, 2021
NCT05024045: Phase 1 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
![](https://static.wixstatic.com/media/cd6738_b880e1b82549434fa06531c352c89e9b~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_b880e1b82549434fa06531c352c89e9b~mv2.webp)
![NCT04942067: Phase 1/2: APG-2575 in Combination With Novel Therapeutic Regimens in RRMM Myeloma](https://static.wixstatic.com/media/cd6738_b880e1b82549434fa06531c352c89e9b~mv2.jpg/v1/fill/w_269,h_179,fp_0.50_0.50,q_90,enc_auto/cd6738_b880e1b82549434fa06531c352c89e9b~mv2.webp)
- Jun 28, 2021
NCT04942067: Phase 1/2: APG-2575 in Combination With Novel Therapeutic Regimens in RRMM Myeloma
![](https://static.wixstatic.com/media/cd6738_368d89e9fd01450a80b12d686b1cdbb1~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_368d89e9fd01450a80b12d686b1cdbb1~mv2.webp)
![NCT04756726: Phase 1/2: CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma](https://static.wixstatic.com/media/cd6738_368d89e9fd01450a80b12d686b1cdbb1~mv2.jpg/v1/fill/w_269,h_182,fp_0.50_0.50,q_90,enc_auto/cd6738_368d89e9fd01450a80b12d686b1cdbb1~mv2.webp)
- Jun 6, 2021
NCT04756726: Phase 1/2: CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
![](https://static.wixstatic.com/media/cd6738_8e52577db1014da4b908b8708875c4a4~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_8e52577db1014da4b908b8708875c4a4~mv2.webp)
![NCT04398485: Phase 1: A Study of ION251 Administered to Patients With Relapsed/Refractory Myeloma](https://static.wixstatic.com/media/cd6738_8e52577db1014da4b908b8708875c4a4~mv2.jpg/v1/fill/w_269,h_180,fp_0.50_0.50,q_90,enc_auto/cd6738_8e52577db1014da4b908b8708875c4a4~mv2.webp)
- Dec 8, 2020
NCT04398485: Phase 1: A Study of ION251 Administered to Patients With Relapsed/Refractory Myeloma
![](https://static.wixstatic.com/media/cd6738_1ffbae89a7bd46769b0094066f7fdc4d~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_1ffbae89a7bd46769b0094066f7fdc4d~mv2.webp)
![NCT04196491: Phase 1 - Evaluate the Safety of bb2121 in High Risk, New Myeloma (NDMM) (KarMMa-4)](https://static.wixstatic.com/media/cd6738_1ffbae89a7bd46769b0094066f7fdc4d~mv2.jpg/v1/fill/w_269,h_186,fp_0.50_0.50,q_90,enc_auto/cd6738_1ffbae89a7bd46769b0094066f7fdc4d~mv2.webp)
- Dec 27, 2019
NCT04196491: Phase 1 - Evaluate the Safety of bb2121 in High Risk, New Myeloma (NDMM) (KarMMa-4)
![](https://static.wixstatic.com/media/cd6738_c04eb567606844f2910297a732f9f5dc~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_c04eb567606844f2910297a732f9f5dc~mv2.webp)
![NCT03412565: Phase 2 - Subcutaneous Daratumumab in Combination With Standard MM Regimens - PLEIADES](https://static.wixstatic.com/media/cd6738_c04eb567606844f2910297a732f9f5dc~mv2.jpg/v1/fill/w_269,h_184,fp_0.50_0.50,q_90,enc_auto/cd6738_c04eb567606844f2910297a732f9f5dc~mv2.webp)
- Dec 14, 2018
NCT03412565: Phase 2 - Subcutaneous Daratumumab in Combination With Standard MM Regimens - PLEIADES
![](https://static.wixstatic.com/media/cd6738_7b184b6cf27e452092aede563c4c092a~mv2.jpeg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_7b184b6cf27e452092aede563c4c092a~mv2.webp)
![NCT03539744: Phase 3 - A Study of Venetoclax/Dex Compared With Pomalidomide/Dex - t(11;14) +ive RRMM](https://static.wixstatic.com/media/cd6738_7b184b6cf27e452092aede563c4c092a~mv2.jpeg/v1/fill/w_269,h_182,fp_0.50_0.50,q_90,enc_auto/cd6738_7b184b6cf27e452092aede563c4c092a~mv2.webp)
- Dec 8, 2018
NCT03539744: Phase 3 - A Study of Venetoclax/Dex Compared With Pomalidomide/Dex - t(11;14) +ive RRMM
![](https://static.wixstatic.com/media/cd6738_d23ed66c82134983908188f3a3b5fbe8~mv2.jpeg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_d23ed66c82134983908188f3a3b5fbe8~mv2.webp)
![NCT01415882: Phase 2: Ixazomib Citrate in Relapsed Multiple Myeloma, Not Refractory to Bortezomib](https://static.wixstatic.com/media/cd6738_d23ed66c82134983908188f3a3b5fbe8~mv2.jpeg/v1/fill/w_269,h_181,fp_0.50_0.50,q_90,enc_auto/cd6738_d23ed66c82134983908188f3a3b5fbe8~mv2.webp)
- Dec 1, 2011
NCT01415882: Phase 2: Ixazomib Citrate in Relapsed Multiple Myeloma, Not Refractory to Bortezomib
![](https://static.wixstatic.com/media/cd6738_a9fca5e2dcbe4f15b2b5ab09e9e7cceb~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_a9fca5e2dcbe4f15b2b5ab09e9e7cceb~mv2.webp)
![NCT00644228 : Phase 3 - Lenalidomide and Dexamethasone + / - Bortezomib in NDMM - SWOG S0777](https://static.wixstatic.com/media/cd6738_a9fca5e2dcbe4f15b2b5ab09e9e7cceb~mv2.jpg/v1/fill/w_269,h_181,fp_0.50_0.50,q_90,enc_auto/cd6738_a9fca5e2dcbe4f15b2b5ab09e9e7cceb~mv2.webp)
- Dec 30, 2008
NCT00644228 : Phase 3 - Lenalidomide and Dexamethasone + / - Bortezomib in NDMM - SWOG S0777
![](https://static.wixstatic.com/media/cd6738_0bdfcda5bfc943b1b0882a0d2baa283c~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_0bdfcda5bfc943b1b0882a0d2baa283c~mv2.webp)
![NCT00114101: Phase 3 - CALGB 100104 - Lenalidomide in Patients With MM Undergoing Auto Transplant](https://static.wixstatic.com/media/cd6738_0bdfcda5bfc943b1b0882a0d2baa283c~mv2.jpg/v1/fill/w_269,h_181,fp_0.50_0.50,q_90,enc_auto/cd6738_0bdfcda5bfc943b1b0882a0d2baa283c~mv2.webp)
- Dec 29, 2005
NCT00114101: Phase 3 - CALGB 100104 - Lenalidomide in Patients With MM Undergoing Auto Transplant
![](https://static.wixstatic.com/media/cd6738_b591eee6387a4a65bc7acb9e07ed6a76~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_b591eee6387a4a65bc7acb9e07ed6a76~mv2.webp)
![NCT00056160 : Phase 3 - CC-5013 (lenalidomide) Dex Vs Dex Alone Previously Treated Multiple Myeloma](https://static.wixstatic.com/media/cd6738_b591eee6387a4a65bc7acb9e07ed6a76~mv2.jpg/v1/fill/w_269,h_179,fp_0.50_0.50,q_90,enc_auto/cd6738_b591eee6387a4a65bc7acb9e07ed6a76~mv2.webp)
- Dec 11, 2003
NCT00056160 : Phase 3 - CC-5013 (lenalidomide) Dex Vs Dex Alone Previously Treated Multiple Myeloma